Creso Pharma Limited
COPHF · OTC
12/31/2023 | 6/30/2023 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $176 | $46,131 | $13,915 | $39,490,151 |
| - Cash | $692 | $0 | $1,388 | $0 |
| + Debt | $9,646 | $0 | $6,671 | $0 |
| Enterprise Value | $9,130 | $46,131 | $19,198 | $39,490,151 |
| Revenue | $11,909 | $7,012 | $4,360 | $4,329 |
| % Growth | 69.8% | 60.8% | 0.7% | – |
| Gross Profit | $8,520 | -$6,185 | -$6,176 | $6,463 |
| % Margin | 71.5% | -88.2% | -141.6% | 149.3% |
| EBITDA | -$3,072 | -$22,085 | -$23,383 | $5,765 |
| % Margin | -25.8% | -315% | -536.3% | 133.2% |
| Net Income | -$24,127 | -$28,319 | -$25,623 | -$7,159 |
| % Margin | -202.6% | -403.9% | -587.7% | -165.4% |
| EPS Diluted | 7.8 | -7.8 | -10.04 | 10.018 |
| % Growth | 200% | 22.3% | -200.2% | – |
| Operating Cash Flow | $11,788 | -$11,788 | -$11,275 | -$19,558 |
| Capital Expenditures | -$133 | -$180 | -$141 | -$207 |
| Free Cash Flow | $3,515 | -$11,969 | -$11,415 | -$19,766 |